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Lung cancers are typically malignant tumors found in one or both lungs. These cancers usually 
form from cells that line the airways and nearby glands because it is these cells that come into 
contact with the air we breathe and the many carcinogens that are contained within it. In the US, 
there are approximately 413,000 people with lung cancer at any given time. Non-small cell lung 
cancer accounts for about 80% of all lung cancer cases. So far, the diagnosis of lung cancer relies 
significantly on physical examination. This late detection usually results in a high probability of 
metastasis and consequently high mortality. Therefore, as the second most common cancer 
diagnosed in US, the earlier detection and therefore treatment of lung cancer has been one of the 
primary goals of researchers. 
   Paclitaxel (Taxol), a microtubule (MT) stabilizing agent originally noted to be useful against 
ovarian and breast cancers, has recently been found to have clinical utility in the treatment of 
lung cancer. A variety of structurally diverse MT stabilizers have been discovered over the past 
decade. These agents include discodermolide, laulimalide and dictyostatin, originally isolated 
from marine sponges, epothilones, originally isolated from the broth of fermenting soil bacteria, 
and eleutherobin, first found from soft corals. Many reports show that these agents have activity, 
all in vitro and some in vivo, against human cancers. Their working mechanism includes the 
 v
enhancement of tubulin assembly into hyperstable microtubules, the G2/M arrest of cells, and the 
induction of apoptosis. As the MT stabilizing action leads to the induction of apoptosis, there 
obviously must be some changes in the affected cells' proteome, including both expression and 
post-translational changes, which are a result of MT stabilization and represent early signals that 
lead to activation of the apoptosis cascade. The goal of the project is to detect and characterize 
the earlier proteomic changes of NSCLC cells after treatment with MT stabilizing agents using 
2-D DiGE and MALDI-TOF. It is expected that a more detailed understanding of NSCLC cells’ 
response to MT stabilizers will allow for more rational decision-making in the clinical treatment 
of diseases. 
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1. INTRODUCTION 
 
The pharmacology of drug discovery includes two main categories. Rational drug design is based 
on biochemical assays that lead to structure-activity relationship (SAR) between the test agent 
molecules and the biological target, and includes computational molecular modeling based on 
the structure of the target (if known) and the structures of the test agents. Cell based drug design 
uncovers new drugs through screening of compounds for their biological effect on target 
function (i.e., test agent-induced change in phenotype). Though cell-based readout systems are 
not as straightforward as the former, the method has shown its importance and is becoming a 
mainstream strategy employed by researchers, mainly because, unlike the former, the cell-based 
systems give a readout of the test agents' activities in living cells. The work done by Issaeva et 
al. on the isolation of a new p53 activator with anticancer properties is one of the successful 
examples from the cell-based strategy [1, 2]. The overall objective of this project is to develop an 
early stage and high information content cell-based screening system for microtubule stabilizing 
agents, with particular emphasis on use of proteomics technologies.  Through wise selection of 
screening strategies and detection methods, novel anti-carcinoma agents with potential of clinical 
application could be found. In addition, the large amount of data from the screening process will 
provide useful information of biological targets, and therefore help gain an understanding of the 
working mechanism of the drugs. 
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1.1. HYPOTHESIS AND SPECIFIC AIMS 
 
A common feature in the working mechanism of different MT stabilizers includes their 
enhancement of tubulin assembly into hyperstable microtubules, the arrest of cells in the G2/M 
phase of the cell cycle, and the induction of apoptosis [3]. The hypothesis is that as the MT 
stabilizing action typically leads to the induction of apoptosis, there are detectable, signature 
changes in the affected cells' proteome. The possible changes as a result of MT stabilization 
include both protein expression levels and post-translational changes, and will represent early 
signals that lead to activation of the apoptosis cascade.  
    The specific aims therefore are to (1) Determine the antiproliferative activity of microtubule 
stabilizing agents on human cancer cell lines; (2) Detect the early stage proteomic changes 
induced by microtubule stabilizers; (3) Identify the biological targets; and (4) Explore the 
mechanism of microtubule stabilizers on human carcinoma cells. 
 
1.2. BACKGROUND 
 
1.2.1. Microtubules and MAPs 
Microtubules (MTs) are intracellular tubes of regular circumference that form cytoskeletal 
lattices and the mitotic spindle. They are built and dismantled from the dynamic 
assembly/disassembly of heterodimers of the ~50kDa proteins α- and β- tubulin, of which 
several isotypes for each monomer exist in mammalian systems [4] (Figure 1).  
    Microtubule dynamics encompasses the multiple reactions involved in the rapid assembly and 
disassembly of microtubules, particularly those forming the spindle. There are two interesting 
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kinds of dynamic behaviors, dynamic instability and treadmilling. The former is a process in 
which the individual microtubule ends switch between phases of relatively slow sustained 
growth and rapid shortening [5]. The latter is the net growth at one microtubule end and the net 
shortening at the opposite end [6]. Many cellular activities, including normal cell division, 
intracellular transport, cellular motility, cell signaling and maintenance of cell shape are all 
dependent on the highly regulated dynamic instability process of the tubulin/microtubule system 
[7]. Therefore, the tubulin/microtubule complex has proven to be a clinically useful antitumor 
target. The examples of chemotherapeutics that act via perturbation of tubulin polymerization 
include paclitaxel (Taxol®), docetaxel(Taxotere®), vinblastine and discodermolide [8-11] 
(Figure 2). Docetaxel is a semi-synthetic derivative of paclitaxel. Unlike the other three 
compounds, which stabilize microtubules, vinblastine aggregates tubulin and leads to 
microtubule depolymerization. 
    There are a large group of microtubule-associated proteins (MAPs) [12] that bind the 
microtubules, acting mainly to stabilize them against disassembly. The binding of MAPs to 
microtubules is largely dependent on MAP phosphorylation status, making them targets for 
protein kinases. MAPs are tissue and cell type specific. Major MAPs include MAP1, MAP2, and 
MAP4 with molecular weights of 200-300 KDa, and the neuronal protein tau (20-60 KDa). 
MAP4 is the most abundant and ubiquitous MAP in non-neuronal cells; it stabilizes microtubules 
[13]. 
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Figure 1: Illustration of microtubule structure. The microtubule is formed as series of 
protofilaments via the noncovalent attachment of tubulin dimers to the plus (growing) end of the 
microtubule. 
 
1.2.2. Microtubule stabilizing agents 
Paclitaxel (Taxol®), a natural product isolated from Pacific yew tree, Taxus brevifolia, is a 
microtubule (MT) stabilizing agent that has demonstrated significant clinical success.   It was 
originally noted to be useful against ovarian and breast cancers.  Recent studies show that it also 
has clinical utility in the treatment of lung cancer [14, 15]. A variety of structurally diverse MT 
stabilizers have been discovered over the past decade. These agents include discodermolide, 
laulimalide and dictyostatin-1, originally isolated from marine sponges [11,16-19], epothilone B, 
originally isolated from the broth of fermenting soil bacteria [20], and eleutherobin, first found 
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from soft corals [21] (Figure 2). Many reports show that these agents have activity, all in vitro 
and some in vivo, against human cancers. Even though the binding site of laulimalide on MTs 
differs from the other MT stabilizers [22], these agents have a common feature in that their 
working mechanism includes enhancement of tubulin assembly into hyperstable microtubules, 
the arrest of cells in G2/M phase of the cell cycle and the induction of apoptosis. 
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Figure 2: Chemical structures of the microtubule polymerization inhibitor vinblastine and the 
depolymerization inhibitors paclitaxel, docetaxel, discodermolide, laulimalide, dictyostatin-1, 
eleutherobin and epothilone B. 
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1.2.3. Working mechanism of MT stabilizing agents 
It is well known that paclitaxel binds to microtubules in cells and arrests cells in mitosis by 
stabilizing mitotic spindle microtubules [23, 24]. This differs from the many agents discovered 
before it (e.g., colchicine, vinca alkaloids), which inhibit tubulin polymerization and cause 
cellular microtubules to disappear. Photoaffinity studies have indicated that pacliaxel binds to the 
beta-tubulin subunit at the N-terminal residues 1-31 and 217-233. Electron crystallography of 
zinc-induced tubulin polymeric sheets has also shown that the binding site of docetaxel and 
paclitaxel is in the interior surface of the microtubule lumen [25-28]. Other MT stabilizing 
agents, e.g., discodermolide, laulimalide, dictyostatin and epothilone B, have all been reported 
that have a similar mechanism of action. Experiments performed independently by different 
groups show that discodermolide and epothilone B competitively inhibits the binding of 
[3H]paclitaxel to microtubules. Such an inhibitory pattern implies that these compounds bind at 
the same (or perhaps an overlapping) site on tubulin as does paclitaxel [29, 30]. This implication 
is merited by a recent finding by Martello et al., which describes a synergistic cytotoxic activity 
of discodermolide with paclitaxel against several cancer cell lines [31]. Dictyostatin also binds to 
the same site on microtubules as does paclitaxel. [Madiraju et al., submitted] Shin et al. have 
reported the synthesis and antiproliferative effects of cyclic discodermolide analogs resembling 
the structure of dictyostatin. The structural similarity between these two agents strongly suggests 
that they share a common binding site on tubulin [32].  A similar competition assay on 
laulimalide was reported by Pryor et al.. The results show that laulimalide is unable to inhibit the 
binding of [3H]paclitaxel or of 7-O-[N-(2,7-difluoro-4’-fluoresceincarbonyl)-L-alanyl]paclitaxel, 
a fluorescent paclitaxel derivative, to tubulin.  This indicates that laulimalide, while as active as 
  7
paclitaxel in promoting cold-stable microtubule spindles, binds to a distinct site on tubulin 
polymer [22]. Currently, a combined strategy of photoaffinity labeling with proteomic method is 
being employed to investigate the laulimalide binding site on microtubules in the Nelson and 
Day groups. 
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2. RESEARCH METHODS AND PRELIMINARY RESULTS 
 
2.1. ANTIPROLIFERATIVE ACTIVITY OF MICROTUBULE STABILIZING 
AGENTS 
 
2.1.1. Introduction 
Antiproliferative assays are widely used to evaluate new agents against carcinoma cells and are a 
part of the drug discovery process. Three microtubule stabilizing agents on hand in the Day 
group were assessed for antiproliferative and potential cytotoxic activity against a panel of 
human carcinoma cells. Six well-established carcinoma cell lines were examined in this assay: 
MDA-MB231 (breast), PC3 (prostate), 2008 (ovarian), 1A9 (ovarian), 1A9/Ptx10 and 1A9/Ptx22 
(ovarian with beta tubulin mutation). These cell lines were chosen in part because they all are 
well-studied in the Day lab. Moreover, these cancer types represent a large percentage of solid 
tumors currently reported in the U.S.A. These cell lines have similar growth characteristics and 
are particularly sensitive to antimitotic agents.  
 
The MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] assay is a colorimetric method for determining the number of viable cells in 
proliferation or cytotoxicity assays.  In this assay, the MTS tetrazolium compound is reduced by 
cells' mitochondria into a colored formazan product that is soluble in tissue culture medium [33]. 
This conversion is presumably accomplished by the NADPH or NADH produced by 
dehydrogenase enzymes in metabolically active cells [34]. Assays are performed by adding a 
small amount of the MTS reagent directly to culture wells, incubating for 1 h and then recording 
absorbance at 490 nm minus that observed at 630 nm with a plate reader. The quantity of 
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formazan product as measured by the amount of 490 nm absorbance is directly proportional to 
the number of living cells in culture [35]. The reference wavelength at 630 nm is used to reduce 
background contributed by excess cell debris, fingerprints and other nonspecific absorbance. The 
MTS assay is a convenient and fast way to determine the cell numbers, thus helping to determine 
the antiproliferative activity of the compounds. 
 
2.1.2. Experimental section 
2.1.2.1. Materials 
 
RPMI medium 1640, penicillin-streptomycin, L-glutamine, and trypsin-EDTA were obtained 
from Invitrogen Co., Carlsbad CA. Fetal bovine serum (FBS) was obtained from Hyclone, 
Logan, UT. Trypan blue solution (0.4%) was obtained from Sigma Co., St. Louis, MO. 96-Well 
plates were obtained from Corning-Costar, NY. Paclitaxel was from the Drug Synthesis Branch 
of the National Cancer Institute. Discodermolide was a gift from Novartis Pharmaceutical Co., 
Laulimalide and dictyostatin were provided, respectively, by Scott Nelson's and Dennis Curran's 
group at the University of Pittsburgh. MDA-MB231, PC3 and 2008 cells were from the ATCC. 
The 1A9 cells and their paclitaxel-resistant clones were gifts from Drs. Tito Fojo and Paraskevi 
Ginnakakou at the National Cancer Institute. 
 
2.1.2.2. Methods 
 
Cells were grown in RPMI 1640 medium with 10% FBS.  Human cancer cells were trypsinized 
and plated into 96-well microtiter plates at 500-2000 cells/well (depending on the cell line), 
allowed to attach and grow for 48 h, and then treated with vehicle (DMSO) or test agent for an 
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additional 72 h. In each case, one plate consisted entirely of cells in medium or medium alone to 
determine time zero cell numbers. The other plates in a given determination contained eight 
wells of control cells, eight wells of medium, and four wells of each agent concentration tested in 
5-fold dilutions. Cell viability was determined with the MTS assay and 50% growth inhibitory 
concentration (GI50) values were estimated and further confirmed by repeating the screen using 
2-fold dilutions centered on the initial estimated GI50 concentration, again in quadruplicate.  
 
2.1.3. RESULTS AND DISCUSSION 
Table 1 shows the effects of the potent microtubule stabilizing agents paclitaxel, discodermolide, 
laulimalide and dictyostatin on carcinoma cell growth. All of the compounds displayed potent 
antiproliferative activity against human carcinoma cell lines. Compared to paclitaxel, 
discodermolide is less potent toward cancer cells and the GI50 values of both are almost within 
the same order of magnitude. Laulimalide is apparently the most potent of the compounds. The 
data show that it is almost two orders of magnitude more potent than discodermolide. Due to the 
interesting and encouraging results, laulimalide was further tested against the 1A9 human 
ovarian cancer cell lines and their palcitaxel-resistant clones, 1A9/Ptx10 and 1A9/Ptx22.  Low 
nanomolar activity was obtained against the two paclitaxel-resistant cell lines 1A9/Ptx10 and 
1A9/Ptx22. Similar results has been reported by Pryor, et al. in Hamel’s group [22] (Table 2).  
The cytotoxicity of laulimalide was examined with a series of human ovarian cancer cell lines in 
comparison with paclitaxel and epothilone A and B. Among six cell lines, A2780/AD10 is a 
multidrug-resistant line that overexpresses P-glycoprotein. 1A9/Ptx10 and 1A9/Ptx22 are 
paclitaxel-resistant lines. A8 and B10 are resistant to epothilones A and B, respectively. The 
latter four lines all have mutations in the M40 β-tubulin gene at amino acid residues near taxoid 
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binding site [36]. From the data in Table 2, we can see that laulimalide, like epothilones A and B, 
is not a good substrate for P-glycoprotein, and remains its antiproliferative activity in 
A2780/AD10 cell line. All four lines with mutation-based paclitaxel/epothilone resistance also 
retain their sensitivity to laulimalide. This result is obviously an indication that laulimalide binds 
tubulin assembly at a new site and might have synergistic cytotoxic activity with compounds 
bound at the taxoid site. 
    Besides of laulimalide, dictyostatin has also been reported that remain potency in paclitaxel-
resistant human cancer cell lines (NCI/ADR-RES and MES-SA/DX5) expressing active P-
glycoprotein [37] (Table 3).  
Table 1: Antiproliferative activities of a panel of MT stabilizing agentsa 
 
GI50 (nM) ± SE 
Compound 
MDA-MB231 PC3 2008 1A9 1A9/Ptx10 1A9/Ptx22
Paclitaxel 2.4 ± 1.6 15 ±2 9.2 ±1.6 0.71 ± 0.11 64 ± 8 51 ± 9 
Discodermolide 16 ± 3 67 ±4 72 ±5 1.7 ± 1.2 6.2±3.6 7.0 ± 8.4 
Laulimalide 0.0839 ± 0.0135 
0.158 ± 
0.011 
0.306 ± 
0.159 <0.08 <0.08 <0.08 
Dictyostatin    0.69 ± 0.80 3.2 ± 2.4 1.3 ± 1.0 
a MDA-MB231 (human breast cancer cell line); PC3 (human prostate cancer cell line); 2008 (human ovarian cancer 
cell line); 1A9 (human ovarian cancer cell line); 1A9/Ptx10 (Phe270->Val beta-tubulin mutation); 1A9/Ptx22 
(Ala364->Thr beta-tubulin mutation). 
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Table 2: Cytotoxic activity of laulimalide in paclitaxel or epothilones resistant human ovarian 
cell lines [excerpted from Pryor et al., ref. 22] 
 
IC50 (nM) ± SE Compound 
1A9 PTX10 PTX22 A8 B10 A2780/AD10
Laulimalide 3.9 ± 0.4 6.0 ± 1 6.3 ± 1 9.2 ± 2 15 ± 0.2 31 ± 0.6 
Epothilone A 1.7 ± 0.3 18 ± 7 4.3 ± 1 93 ± 30 125 ± 25 16 ± 0.6 
Epothilone B 0.17 ± 0.08 0.70 ± 0.4 0.32 ± 0.2 6.4 ± 4 9.0 ± 5 2.6 ± 2 
Paclitaxel 1.7 ± 0.3 50 ± 11 34 ± 3 13 ± 2 16 ± 4 4000 ± 900 
 
Table 3: Cytotoxic activity of dictyostatin and paclitaxel in human cancer cell lines following 72-
hr exposure to the test agents [excerpted from Isbrucker et al., ref. 37]. (Values in brackets are 
relative fold resistance, indicating the reduced potency of the compound in the resistant cell 
lines.) 
 
IC50 (nM) ± SE Cell line 
Dictyostatin-1 Paclitaxel 
A549 0.95 ± 0.25 5.13 ± 2.9 
MCF-7 1.5 ± 0.9 2.5 ± 0.7 
NCI/ADR-RES 20 ± 4.2 (13×) 3331 ± 652 (1332×)
MES-SA 4.1 ± 1.4 3.3 ± 0.6 
MES-SA/DX5 11 ± 2.4 (3×) 1654 ± 230 (501×)  
 
 
2.2. PROTEOMIC CHANGES INDUCED BY MICROTUBULE STABILIZING 
AGENTS 
 
2.2.1. Introduction 
The hypothesis to be tested in the present work is that because the MT stabilizing action well 
proceeds the induction of apoptosis, there must be some changes in the proteome of the affected 
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cells, including both expression level and post-translational changes.  Significant changes in the 
proteome of breast cancer cells treated with MT stabilizers have been shown in the literature to 
become apparent after a long time of treatment [38]. Few proteomic changes have yet to be 
detected in the shorter treatment times. In this study, human non-small cell lung cancer cell line 
H460 was selected with a short treatment time (6 h). 
    The experimental work flow was designed to consist of eight parts as shown in Figure 3, 
including cell culture, treatment of cancer cells with drugs for different time periods, cell lysis 
and protein clean-up, labeling of control and drug treated samples with electrophilic fluorescent 
dyes (staining) and separation of a treated sample combined with its vehicle control cell sample 
by 2D gel electrophoresis, gel image acquisition and analysis, protein identification by modern 
mass spectrometry (e.g., MALDI-TOF/TOF-MS/MS) and database searching with the results, 
and Western blotting for protein identity verification. 
    In order to separate two samples on the same gel, a new technique known as difference gel 
electrophoresis (DiGE) was employed instead of traditional 2D gel electrophoresis (Figure 4) 
[39]. The primary benefit of this technique is that the gel-to-gel variation arising in actual 
operation can be avoided. Two electrophilic fluorescent cyanine dyes, PrCy3-N-
hydroxysuccinimide ester and MeCy5-N-hydroxysuccinimide ester (Cy3 and Cy5, respectively), 
are used to label two different samples. These dyes are of the same molecular weight (Figure 5) 
and are bound covalently to 1-3% of the available lysine side chains (Figure 6) [40]. This low 
level of binding does not cause significant alteration of the protein isoelectric points (pIs). This 
strategy can even be optimized by involvement of a third dye, an electrophilic form of Cy2, with 
charge and size matched to Cy3 and Cy5, as an internal standard labeled to a third sample [41]. 
The gel image scanning and sample picking was performed using a custom-built instrument with 
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a high-resolution cooled Prometrix® CCD camera (CH350 model, 16 bit chip, Photometrics, 
Munich, Germany) capable of imaging Cy2, Cy3 and Cy5 dyes. The colors and excitation and 
emission wavelengths of the Cy dyes are shown in Figure 7 and Table 4.  
 
 
        
 
 
 
 
Figure 3: Flow diagram illustrating the overall experimental process in proteomics 
 
 
 
 
 
 
 
 
 
 
Figure 4: Schematic representation of DIGE [excerpted from Unlu et al., ref. 39] 
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Figure 5: Chemical structures of Cy3 (left), Cy5 (middle) and Cy2 (right) 
 
N N
O
O
NO O
)( n
m=1, n=1: Cy3
m=0, n=2: Cy5
+
H2N
NH2
N
H
O
protein
pH > 8
m
NH2
N
H
O
protein
N N
)( n
+
HN
O
m
 
 
Figure 6: Possible mechanism of Cydye labeling with lysine side chain: an amide is formed 
through nucleophilic substitution. 
 
 
Figure 7: Visual appearances of Cy3, Cy5 
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Table 4: Parameters of three cyanine dyes 
 
 
 
 
 
 
    By using software accompanying the gel imaging station, two-frame, “flash” movies of the 
overlying Cy3 and Cy5 images were viewed in a continuous loop to visually detect the 
differences in the protein patterns between the two samples separated in the same gel. The result 
was further confirmed and quantified by using DeCyder Differential Analysis software 
(Amersham Biosciences Inc.). DeCyder analyzes images as fragments, summed to generate a 
composite image, with proprietary algorithms that detect overlapping, differently colored images 
within the same gel to match spots and subtract background for normalization. DeCyder creates 
measurement masks, each outlining an area of the gel containing a protein spot, which were 
applied to each of the matching fragments in the paired fluorescent images of each gel. The 
masks define areas in which the pixel values were integrated to create three dimensional 
topographical maps with peaks representing each protein spot.  An estimate of the local 
background for each spot determined the base values across the masked area.  Output from the 
image analysis, designated as fluorescence intensity, was the sum of pixel values in the mask 
area minus the background.  Volumes of the peaks representing the relative strengths of 
fluorescent signals from the matched spots were compared [42]. The Melanie 4 viewer (Swiss 
Institute of Bioinformatics, Switzerland), ImageJ (http://rsb.info.nih.gov/ij/) and V++® Precision 
CyDyes 
Excitation 
Wavelength 
(nm) 
Emission  
wavelength
(nm) 
Cy2 489 506 
Cy3 552 570 
Cy5 643 667 
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Digital Imaging System (Digital Optics Ltd) are presently being explored in a combined use 
manner to achieve the best results for image analysis. 
 
2.2.2. Experimental section 
2.2.2.1. Materials  
 
Carcinoma cells were from ATCC (American Type Culture Collection), Manassas, VA. 
MT stabilizing agents were from our collaborators. Tris-base, glycine, SDS, Coomassie G250 
Stain, Tween-20, polyvinylidene difluoride (PVDF) membrane were obtained from Bio-Rad 
Laboratories, Hercules, CA. 2-Mercaptoethanel, ammonium bicarbonate was from Sigma, St. 
Louis, MO.  Paclitaxel was from NCI Drug Synthesis Branch. ProtoGel 30% (w/v) acrylamide: 
0.8 % (w/v) bis-acrylamide stock solution was from National Diagnostics, Atlanta, GA. TGS 
buffer, MES buffer, MOPS buffer, carrier ampholytes, IPG strips and PROTEAN II gels were 
from Bio-Rad. ReadyPrep 2D Cleanup  Kit, including precipitating agent 1 and 2, wash agent 1 
and 2 and wash agent 2 additive, were from Bio-Rad, Hercules, CA. The 2D Quant kit was from 
Amersham Biosciences, Piscataway, NJ.  Cy-dyes were synthesized in Professor Day’s lab 
according to a previously published method [39]. Protease inhibitor cocktail and phosphatase 
inhibitor cocktail were from EMD Biosciences, Inc., La Jolla, CA. Anti-stathmin antibody 
(rabbit) was from Santa Cruz Biotechnologies.  Peroxidase labeled anti-rabbit antibody (mouse) 
was from Amersham Life Sciences. 
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2.2.2.2. Methods 
 
Cell culture and cell lysis Human carcinoma cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS).  Cells were treated 
with different MT stabilizing agents at their GI90 concentrations for 6 h. After harvest, cells 
were centrifuged at 1000g and washed with Hank’s buffer three times.  Cell lysis was performed 
in 6 M urea, 2 M Thiourea, 100 mM DTT, 4% CHAPS and 10 mM HEPES plus additives (1 mM 
PMSF, 1.5 mM EDTA, 2 µg/ml aprotinin, 10 µg/ml leupeptin, 1 µg/ml pepstatin-A, 10 mM 
sodium fluoride and 1 mM sodium orthovanadate). The lysate was ultracentrifuged at 200,000g 
for 1 h at 4 °C and the supernatant was kept at –80°C for later use. 
Acetone protein precipitation The cell lysate protein sample was placed in an acetone-
compatible tube followed by adding four volumes of cold acetone (-20°C). The mixture was 
vortexed and incubated for 2~3 h at -20°C. A subsequent 10 min centrifugation step at 16,000g 
at 4 °C was performed. The supernatant was decanted and properly disposed. The pellet was 
dried in air and then resuspended in lysis buffer until fully dissolved. The sample was stored at  
–80°C until ready for use. 
Protein sample clean-up (alternative to acetone protein precipitation) The protein sample 
(100-500 µg) in a final volume of 100 µL was transferred into a 1.5 mL micro-centrifuge tube. 
Then 300 µL of precipitating agent 1 was added and mixed by vortexing. After incubation on ice 
for 15 min, 300 µL of precipitating agent 2 was added and the contents mixed by vortexing. The 
tubes were centrifuged at >12,000g for 5 min to form a tight pellet. The supernatant was 
decanted and the tubes were repositioned as before and centrifuged. Any residual liquid at the 
bottom of the tubes was removed. Then, 40 µL of wash agent 1 was added on top of the pellet 
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and the tubes were centrifuged at >12,000g for 5 min. The supernatant was removed and 
discarded. Ultrapure water (25 µL) was added to the tubes and the contents mixed by vortexing 
10~20 sec.  An additional 1 mL of wash agent 2 (pre-chilled at –20°C for > 1 h) and 5 µL of 
wash 2 additive were mixed by vortexing for 1 min.  During the following incubation period (at 
–20°C for 30 min), the tubes were vortexed for 30 sec at every 10 min interval. The pellet was 
formed by centrifugation at >12,000g for 5 min. The supernatant was discarded and the pellet air 
dried for < 5 min (The pellet became translucent once sufficiently dry). The pellet was 
resuspended by adding lysis buffer followed by vortexing for 1 min, incubation at room 
temperature for 3~5 min and vortexing again for 1 min. The tubes were centrifuged at >12,000g 
for 2~5 min to clarify the protein sample. The supernatant was then ready for isoelectric focusing 
(IEF). The remaining sample was stored at –80°C for later use. 
Protein quantitation assay  
1. Bradford Assay (CBB Assay) The protein sample (2 µL) was added to a 
1.5 mL Eppendorf tube and treated with 800 µL of H2O and 200 µL of Coomassie Protein Assay 
Reagent (stored at 4 °C). The estimated final concentration of the protein in each sample was 1-
20 µg/mL. Protein standards were prepared containing a range of 1 to 20 µg protein (albumin or 
gamma globulin) the same way to a final volume of 1 mL. The mixtures were vortexed briefly. 
The absorbance of each sample was read at 595 nm on a SpectraMax Plus UV detector 
(Molecular Devices). The concentration was calculated from the standard calibration curve. 
Good detection limits were 1-20 µg with a non-linear standard curve [43]. 
2. 2-D Quant Kit Tubes containing 1~50 µL of each sample were prepared to 
be assayed in duplicate.  The tubes were treated with 500 µL of precipitant solution, vortexed 
briefly and incubated for 2-3 min at room temperature. Another 500 µL of co-precipitant solution 
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was added and the contents mixed briefly by vortexing or inversion. The tubes were centrifuged 
at a minimum of 10,000g for 5 min.  The supernatant was decanted and the tubes were 
centrifuged again.  Any liquid remaining was then removed. The pellets were treated with 100 
µL of copper solution and 400 µL of de-ionized water to dissolve the pellet. Another 1 mL of 
working color reagent was added and mixed by inversion. The contents were incubated at room 
temperature for 15-20 min.  The absorbance of each sample was read at 480 nm using water as 
the reference. The concentration of protein was calculated from a standard curve built with 
bovine serum albumin. The linear response range of the assay was 0.5~50 µg. 
Cy-dye labeling 
Cy-dye stock solutions (8.6 mM) were prepared in the Day lab by dissolving the solid dyes 
separately in anhydrous DMF and aliquoting into 10 µL working solutions. The stock solution 
was stored at –80°C.  
    Equal amounts of protein samples (lysates from DMSO-treated control vs. drug-treated cells) 
were placed into four tubes (two for each sample). The final volume in each tube was equalized 
with lysis buffer. The samples were labeled in a reciprocal manner as shown in Table 5. 
    Each tube was treated with 1.0 µL of the PrCy3-OSu or 0.44 µL of the MeCy5-OSu DMF 
solution and incubated on ice in the dark for 20 min. Afterwards, 1.0 µL of a hydroxysuccinide 
ester-quenching solution (5 M methylamine in 100 mM HEPES, pH 8.0) was added and the 
samples incubated on ice in the dark for another 30 min. The paired tubes (Cy3 and Cy5 for each 
gel) were pooled and mixed well. An ampholyte solution (Bio-Lyte 3/10) (2 µL) was added to 
each tube (final concentration of ampholyte is ~0.2% (v/v)) and the contents were mixed well for 
rehydration. 
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Table 5: Principle of reciprocal labeling in 2D-DiGE experiments 
 
 
 
 
 
 
IEF focusing  Each sample (50-100 µg) was prepared in a rehydration buffer (6 M urea, 
2 M Thiourea, 2% CHAPS, 25 mM DTT, 0.2% 3~10 Ampholyte [depending on the IPG strip 
used] and 2 mM glacial acetic acid) to a final volume  that was dependent on the method of IPG 
strip loading, e.g., 120 µL for cuploading of an  11 cm strip; 185 µL for active/passive 
rehydration of an 11 cm strip; 300 µL for active/passive rehydration of a 17 cm strip. The 
indicated volume of each sample was pipeted as a line along the back edge of a channel in the 
IPG focusing tray. The strip was placed with gel side down onto the sample solution and bubbles 
were removed as much as possible. Each channel was overlaid with mineral oil.  The tray was 
transferred to the cooling platform in PROTEAN IEF cell and isoelectric focusing was initiated 
with the program shown in Table 6. 
2-D gel electrophoresis After first dimension isoelectric focusing, strips were incubated in 
an equilibration buffer (50 mM Tris, pH 8.6, containing 6 M urea, 30% glycerol and 2% SDS) 
containing 1% DTT for 15 min, and then incubated in the same buffer containing 4% 
iodoacetamide (IAA) for another 15 min. The equilibrated strips were placed on 8-16% gradient 
Tris-HCl polyacrylamide gels, and the separation continued at constant Watts in the running 
buffer (25mM Tris, pH 8.8, containing 192 mM glycine and 0.1% SDS) following the program 
shown in Table 7. 
 
 Gel 1 Gel 2 
Control Cy3 Cy5 
Drug-treated 
sample 
Cy5 Cy3 
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Table 6: Isoelectric focusing program  a) Passive/Active rehydration for 11 cm IPG strip; b) 
Passive/Active rehydration for 17 cm IPG strip and c) Cuploading for 11 cm IPG strip. 
a) 
Method: Linear 
Rehydration: Passive/Active 
Run Temperature: 20°C 
IPG Strip: pH 3~10, 11 cm 
Step 1:         250 V                 Ramp: R                 Time: 00:15      
Step 2:         8,000 V              Ramp: L                  Time: 02:00 
Step 3:         8,000 V              Ramp: R                  Vhour: 30,000
Step 4:         500 V                 Hold                        Time: 99:00 
Focusing current: 50 µA/strip 
 
b) 
Method: Linear 
Rehydration: Passive/Active 
Run Temperature: 20°C 
IPG Strip: pH 3~10, 17 cm 
Step 1:         250 V                 Ramp: R                  Time: 00:15      
Step 2:         10,000 V            Ramp: L                  Time: 03:00 
Step 3:         10,000 V            Ramp: R                  Vhour: 60,000
Step 4:         500 V                 Hold                        Time: 99:00 
Focusing current: 50 µA/strip 
 
c) 
Method: Linear 
Rehydration: Cuploading 
Run Temperature: 20°C 
IPG Strip: pH 3~10, 11 cm 
Step 1:         250 V                 Ramp: R                  Time: 00:30      
Step 2:         8,000 V              Ramp: L                  Time: 04:00 
Step 3:         8,000 V              Ramp: R                  Vhour: 40,000
Step 4:         500 V                 Hold                        Time: 99:00 
Focusing current: 50 µA/strip 
 
Table 7: Constant Watt program set in second dimension gel electrophoresis. 
 
 
 
Step 1:             2 W/gel               Time: 30 min  
Step 2:             5 W/gel               Time: 30 min 
Step 3:           10 W/gel               Time: 30 min 
Step 4:           20 W/gel               Time: 30 min 
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Protein visualization and image analysis The gels were fixed overnight in water containing 
40% v/v methanol and 5% v/v acetic acid. The gel image scanning and sample picking was 
performed using a custom-built instrument with a high-resolution cooled Prometrix® CCD 
camera capable of imaging Cy2, Cy3 and Cy5 dyes. DeCyder Differential Analysis software 
("DIA" from Amersham Biosciences Inc.) was used to normalize and analyze the digitalized gel 
images. To confirm the analysis results obtained with DIA, the gels were further stained in 
SyproRuby staining solution overnight to achieve the maximal linear response of the signal. The 
gels were then washed in water containing 10% v/v methanol and 7% v/v acetic acid twice  (1 h 
for each wash) followed by gel scanning. 
SDS-PAGE and immunoblot analysis Protein samples were incubated in SDS sample 
buffer (60 mM Tris, pH 6.8, containing 2% SDS, 10% glycerol, 5% β-mercaptoethanol and 0.5% 
bromophenol blue) at 95 ºC for 5 min and then segregated by SDS-PAGE using the method of 
Laemmli [44].  The resolved proteins were transferred onto PVDF membranes using a Bio-Rad 
Trans-Blot Semi-Dry transfer system at 15 V for 60 min in transfer buffer (25 mM Tris 
containing 19 mM glycine and 20% v/v methanol). After washing in wash buffer (50 mM Tris, 
pH 7.4, containing 0.5 M NaCl and 0.1% v/v Tween 20), the blots were blocked with 5% (w/v) 
nonfat dry milk (blocking agent) in washing buffer. The blots were incubated at 4 ºC overnight 
with polyclonal rabbit anti-stathmin antibody at 1:20,000 dilution, followed by secondary 
reaction with horseradish peroxidase-conjugated anti-rabbit antibody at 1:50,000 dilution for 1 h. 
The Amersham ECL chemiluminescence system and Fuji film were used to detect the protein 
bands. The density changes of bands could be measured using ImageJ software or a 
densitometer. 
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2.2.3. Results and discussion 
In the first experiment, the H460 NSCLC cell line was treated with the MT stabilizing agent 
paclitaxel (50 nM, 1 × GI90 value) or with vehicle (DMSO) for 6 h. Cell lysates were prepared 
and the protein samples were purified and labeled in a reciprocal manner with PrCy3-OSu and 
MeCy5-OSu as outlined above. Aliquots of each sample (control and drug-treated, 50 µg of 
each) were pooled and resolved in a 11 cm, pH 3-10 NL IPG strip followed by a second 
dimensional separation on a Bis-Tris gel.  DeCyder software was used to detect the sample-
dependent differences in protein distribution. Four values of threshold of volume ratio were 
examined (2.0, 1.5, 1.2 and 1.0 fold) to screen for differences.  Dust and artifacts were detected 
as peaks with slope values of less than one or as clusters of sharp spikes. The results of image 
analysis showed that there was no detectable proteomic change (volume ratio > 1.2 fold), either 
expressional or post-translational (e.g., phosphorylation).  The possible reasons for this lack of 
difference in the proteomes might be as follows. First, the treating time was short and hence 
there was no significant proteomic change induced. Second, the gel used for protein segregation 
was too small in dimensions to separate proteins as well as needed to detect differences. The 
expression level changes in the low abundant protein could be hidden by the overlapping high 
abundant proteins. Third, the amount of protein loaded onto the gel was perhaps insufficient to 
detect small changes. Therefore, the low abundant proteins were not detected.  Fourth, the 
protein sample was perhaps not purified enough. Some contaminant or unexpected ingredient 
existing in the whole cell lysate might affect IEF focusing and further the second dimensional 
protein pattern. 
    Two approaches could solve the first problem. One would be to extend the drug treatment 
time; another would be to replace paclitaxel with a different MT stabilizing agent that causes a 
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faster response in the same cell line. Obviously, the latter is a better solution, as it would not alter 
the original objective of the project, which is to search for a cell-based, early stage screening 
method for MT stabilizers. Referring back to the data shown in Table 1, it was therefore decided 
to employ discodermolide as the test agent. Two parallel experiments were performed based on 
the treatment of H460 human non-small cell lung carcinoma cells with 1 x GI90 and 2 x GI90 
concentrations of discodermolide. IPG strips of 17 cm length and pH 3-10 (nonlinear, "NL") 
range were employed to pursue a better first-dimensional focusing and 183 x 193 x 1 mm 
PROTEAN II gels (8-16% gradient) were used for optimal second-dimensional separation. After 
electrophoresis, the gels were scanned and two pairs (control and drug-treated labeled each with 
Cy3 and Cy5 for each concentration) of digitized images were analyzed with DeCyder software. 
More than 2000 spots were detected for each gel image. The spot intensities were normalized 
first by subtraction of the local estimates of background and then by adjustment of signals to 
compensate for dye-specific system gain.  A conservative exclusion filter was subsequently 
applied to reject spots caused by dust particles [45].  Finally, two spots with mid-level changes in 
expression were detected for each pair (Cy3 and Cy5 labeled) of gel images. The two spots on 
the image of 1 x GI90 concentration were further confirmed to be identical to the two spots on the 
image of 2 x GI90 concentration based on protein distribution pattern, molecular weight and pI 
value (Figure 8-12). Table 8 shows the values of the volume ratio changes of the two spots. 
Since the control (DMSO treated) and the sample (drug treated) were labeled by Cy3 and Cy5 in 
a reciprocal manner, a pair of increasing and decreasing volume ratio change values must be seen 
in order for the hypothesis that changes in expression to be accepted. Otherwise, a pair of values 
with the same sign could be from preferential labeling of one of the two cyanine dyes, meaning 
ununiformity of labeling.  
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Table 8: DeCyder DIA image analysis results on reciprocal labeled gels from H460 cells treated 
with discodermolide. 
 
Gel images             Spot Index  Cy3 Cy5 Volume ratio changes 
101404_D300_DM A2 D300 DMSO - 1.59 
101404_DM_D300  A2 DMSO D300 +1.37 
101404_D600_DM  A2 D600 DMSO - 1.71 
101404_DM_D600  A2 DMSO D600 +1.67 
     
101404_D300_DM  A1 D300 DMSO +1.68 
101404_DM_D300  A1 DMSO D300 - 1.04 
101404_D600_DM  A1 D600 DMSO +1.62 
101404_DM_D600  A1 DMSO D600 - 1.56 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: SyproRuby stained gel image acquired after electrophoresis of whole cell lysate of 
H460 cell line treated with discodermolide.  The blue squares encompass two spots detected to 
have expression changes. The orange dashed circles cover the around area showing the specific 
pattern in which phosphorylated isoforms might exist. 
pI:3 pI:10
Mw 
decreasing 
A1 
A2
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Figure 9: Output of image analysis with DeCyder on gels from DMSO- and discodermolide-
treated H460 cell lysates reciprocally labeled with PrCy3-OSu and MeCy5-OSu at 1 × GI90 
concentration, showing the position of spot A1 and its 3-D topographical map.
A1 A1 
A1 A1 
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Figure 10: Output of image analysis with DeCyder on gels from DMSO- and discodermolide-
treated H460 cell lysates reciprocally labeled with PrCy3-OSu and MeCy5-OSu at 2 × GI90 
concentration, showing a zoom-in of the position of spot A1 and its 3-D topographical map.
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Figure 11: Output of image analysis with DeCyder of gels from DMSO- and discodermolide-
treated H460 cell lysates reciprocally labeled with PrCy3-OSu and MeCy5-OSu at 1 × GI90 
concentration, showing the zoom-in of the position of spot A2 and its 3-D topographical map. 
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Figure 12: Output of image analysis with DeCyder on gels from DMSO- and discodermolide-
treated H460 cell lysates reciprocally labeled by PrCy3-OSu and MeCy5-OSu at 2 × GI90 
concentration, showing the zoom-in of the position of spot A2 and its 3-D topographical map. 
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2.3. PROTEIN IDENTIFICATION BY MASS SPECTROMETRY 
 
2.3.1. Introduction 
Mass spectrometry has developed into a powerful tool to analyze proteins for  information such 
as the protein sequence, some  three dimensional structure information, as well as any post-
translation modifications of the protein[46-48].  With the matrix-assisted laser desorption 
ionization (MALDI) method, nonvolatile molecules can be readily introduced into the gas phase 
and analyzed by mass spectrometry. The MALDI sample consists of a solid mixture of analyte 
mixed with a crystalline matrix on a sample plate. The mixture is excited by laser light resulting 
in ions that are guided by optics through a mass analyzer and into an ion detector (Figure 13). 
The matrix is an organic acid with a chromophore absorbing at the laser wavelength, such as α-
cyano-4-hydroxycinnamic acid (Figure 14). Generally, the low mass region of such spectra, 
below ~500 Da, is obscured by the presence of signals from matrix cluster ions. 
    Enzymatic digestion has been employed extensively as a standard method in proteomic 
analysis. Typical enzymatic or chemical cleavage methods are listed in Table 9. An enzyme of 
low specificity, which digests proteins to a mixture of free amino acids and di- and tri- peptides 
(e.g., Pronase E), is not a good choice. A complex mixture containing large numbers of 
components of similar mass will result in a complex spectrum consisting of overlapping ion 
signals. In practice, it is best to use enzymes of specificity equal to or greater than trypsin. 
Trypsin hydrolyzes polypeptides on the carboxyl side of arginine and lysine residues. In-gel 
digestion of polyacrylamide gel electrophoresis (PAGE) separated proteins has proved to be an 
efficient method to generate peptide fragment mixtures for mass spectrometric analyses. Based 
on the peptide mass fingerprint (PMF) information and if a tandem MS system is available, the 
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peptide fragments can be selected as precursors for further fragmentation. A series of fragment 
ions are produced, within which the y type and b type ions (Figure 15) are predominant. The 
database is then searched based on the PMF data combined with MS/MS sequence information. 
 
 
 
 
 
 
 
Figure 13: Illustration of MALDI 
 
        
        
        
        
         
Figure 14: The chemical structure of the matrix molecule: α-cyano-4-hydroxycinnamic acid 
(CHCA) 
 
 a)    b)   c)  
 
Figure 15: A generic example showing a) an immonium ion, b) an internal ion and c) x, y, z, a, b, 
and c ion series. 
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H
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Table 9: Typical enzymatic and chemical cleavage methods used in proteomics. 
 
Name Site of Cleavage Will not 
cleave after 
N or C terminal 
Typsin K, R P C term 
Arg-C R P C term 
Asp-N B, D  N term 
Asp-N_ambic D, E  N term 
Chymotrypsin F, Y, W, L, I, V, M P C term 
CNBr M  C term 
Formic_acid D  C term 
Lys-C K P C term 
Lys-C/P K  C term 
PepsinA F, L  C term 
Tryp-CNBr K, R, M P C term 
TrypChymo F, Y, W, L, K, R P C term 
Trypsin/P K, R  C term 
V8-DE B, D, E, Z P C term 
V8-E E, Z P C term 
M  C term CNBr + Trypsin 
K, R P C term 
 
 
2.3.2. Experimental section 
2.3.2.1. Materials 
 
Both sequencing grade and Gold grade trypsin were from Promega, Madison, WI. CHCA matrix 
was from Sigma and recrystallized in the Day lab. Ammonium bicarbonate and formic acid were 
obtained from Sigma, St. Louis MO. Acetonitrile and methanol were obtained from Fisher, 
Fairlawn, NJ. 
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2.3.2.2. Methods 
 
In gel tryptic digestion After staining the 1-D SDS-PAGE gels with Coomassie blue, the 
bands of interest were excised and soaked in 1:1 (v/v) methanol-50mM aq. NH4HCO3 for 30 min 
with shaking for full destaining. The supernatant was removed and the destaining process was 
repeated one more time. Then the gel pieces were treated with 100% acetonitrile for 5-10 min. 
Enough aq. 10 mM DTT/25 mM NH4HCO3 was added to cover each individual gel piece and the 
mixtures were incubated at 56 ºC for 1 h with shaking for reduction of any disulfide bonds. The 
supernatant was removed and 50 mM iodoacetamide/25mM NH4HCO3 was added for alkylation 
of cystein sulfhydryls (thiol, -SH) followed by incubation in the dark for 45 min at room 
temperature. The supernatant was removed and 25 mM NH4HCO3 was added. After 10 min of 
vortex mixing, the supernatant was removed and the gel plugs were soaked in 1:1 (v/v) CH3CN-
25mM aq. NH4HCO3 for 5 min with vortex mixing. The same process was repeated and then the 
gel pieces were completely dried in a Speed-Vac. For gel pieces excised from 2-D gels, 
reduction and alkylation was not performed. After these gel pieces were washed with 1:1 (v/v) 
methanol-50 mM aq. NH4HCO3 two times, 100% acetonitrile was added with 5-10 min of 
shaking and then the pieces were dried in a Speed-Vac. The dried gel pieces were kept at -4 ºC 
until ready for tryptic digestion. 
    Tryptic digestion was performed via the addition of 10 µL of trypsin (20 ng/µL) in 25 mM 
aqueous ammonium bicarbonate and incubation at ambient for 10-15 min for full rehydration, 
followed by incubation at 42 ºC for 4 h with agitation. The trypsin solution in each tube was then 
transferred to a new clean tube. The remaining gel pieces were treated with 60 µL of 1% TFA in 
50% aqueous acetonitrile for 30 min two times. The extracts of each treatment were pooled with 
the trypsin solution and the mixtures were dried in a Speed-Vac.  
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Mass spectrometric analysis A saturated solution of CHCA was prepared in 0.3% TFA 
in 50% aqueous acetonitrile containing 1 mM ammonium citrate. Recovered peptides were 
resuspended in 3 µL of 0.3% TFA in 50% aqueous acetonitrile containing 1 mM ammonium 
citrate and then diluted with the saturated CHCA solution. Samples (0.7 µL) were spotted onto 
the stainless steel MALDI plate and allowed to dry. Masses of peptides were determined using 
an Applied Biosystems 4700 MALDI-TOF-MS (Applied Biosystem, MA). Internal calibration 
was performed using trypsin autolysis signals (m/z 842.51 and 2211.10). Peptide sequences were 
determined using MALDI-TOF/TOF-MS/MS with 1 kV fragmentation with ambient air as the 
collision gas and spectra were externally calibrated with an MS/MS spectrum from the m/z 
1570.68 [M+H]+ ion (Glu1-Fibrinopeptide B).  Database searching was performed using GPS 
Explorer software (Applied Biosystems, MA) or using online search engines, e.g., Mascot 
(http://www.matrixscience.com/search_form_select.html), 
 MS-Fit (http://prospector.ucsf.edu/ucsfhtml4.0/msfit.htm), 
 or Profound (http://prowl.rockefeller.edu/profound_bin/WebProFound.exe). 
 
2.3.3. Results and discussion 
The protein identification was performed based on the combined PMF and peptide sequence 
information acquired from MALDI-TOF experiments. The results showed that two spots, A1 and 
A2 (Figure 8.), were the proteins stathmin and eukaryotic elongation factor 1 gamma (EEF1G), 
respectively (Figure 16-17, Table 10-14).  
    Stathmin is a well conserved and highly expressed protein in proliferating cells and neurons. 
Its expression level changes markedly during development, cellular differentiation and tissue 
regeneration, and is elevated in some neoplastic cells [49]. Depending on its phosphorylation 
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status, stathmin either inhibits microtubule polymerization or destalibizes microtubules by 
sequestering free tubulin heterodimers. The destabilization activity occurs in the non-
phosphorylated form. Phosphorylation occurs at four serines of stathmin, residues 16, 25, 38 and 
63 [50]. These four phosphorylation sites are targets of multiple kinases, e.g., mitogen-activated 
protein (MAP) kinase for Ser25, cyclin-dependent kinases (Cdks) for both Ser25 and Ser 38, 
protein kinase A (PKA) for Ser16 and Ser63, and Ca2+/calmodulin-dependent kinase-Gr (CaMK 
IV/Gr) for Ser16 [49]. Although there are various phophorylation combinations, it appears that 
phosphorylaion at Ser16 and Ser63 inhibits stathmin to a greater extent than phosphorylations at 
Ser25 and Ser38 [51-53]. Figure 18 illustrates the phosphorylation mediated regulation of 
stathmin activity during cell cycle progression [54]. In the present experiments, the expression 
level of stathmin was found to be decreased in discodermolide-treated cells with respect to their 
DMSO-treated control. The reason might be that discodermolide stabilizes the microtubules and 
leads to a decrease in concentration of free tubulin. Consequently, the low level of tubulin 
concentration could result in decreased expression of stathmin.  
    Eukaryotic elongation factors (EEF) include both EEF1 and EEF2. EEF1 consists of two 
different subfactors: EEF1A and EEF1B. EEF1A (formerly eEF1α) is a single polypeptide while 
EEF1B is a multitrimer of EEF1Bα (formerly eEF1β), EEF1Bβ (formerly eEF1δ) and EEF1Bγ 
(formerly eEF1γ) polypeptides. In general, the process of protein elongation is composed of two 
steps, the recruitment of amino-acylated tRNA to an existing ribosome/mRNA complex and the 
translocation of the ribosome along the mRNA as amino acids are added to the protein. EEF1A 
and EEF1B regulate the recruitment and EEF2 controls the translocation. As shown in Figure 19, 
one EEF1B complex can associate with two EEF1A proteins. The EEF1B consists of either one 
molecule of each of EEF1Bα and EEF1Bβ or two molecules of EEF1Bα, or two molecules of 
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EEF1Bβ. Both EEF1Bα and EEF1Bβ function to exchange GTP for GDP on EEF1A, and 
EEF1Bγ has no known enzymatic activity but facilitates the physical association of EEF1Bα or 
EEF1Bβ with each other or with EEF1A [55]. 
    Furthermore, EEF1A, has also been reported to be a microtubule-servering factor [56]. Its 
microtubule-servering activity can be inhibited by the addition of free tubulin or of the 
microtubule-associated proteins p220 [57] or MAP2 [58]. Because microtubule reorganization 
occurs during the transition from interphase to mitosis, an unregulated elevated level of 
expression of EEF1A might be related with cell death [59]. However, some other reports found 
that both EEF1A1 and EEF1A2 inhibit apoptosis [60-62]. The present data showed an increased 
level of EEF1Bγ in the drug-treated sample compared to the DMSO-treated control. A possible 
explanation of this phenomenon might be that the carcinoma cells are attempting to elevate the 
expression level of EEF1A as a response against the apoptosis inducing actions of 
discodermolide, a microtubule stabilizing agent. Accordingly, EEF1Bγ might also be over-
expressed because it serves to couple EEF1Bα and EEF1Bβ to EEF1A and therefore activate 
EEF1A’s GTP exchanging activity. 
    Besides spots A1 and A2, other spots without detectable expression changes were also 
identified for protein cataloguing purposes. Table 15 and 16 list the results based on experiments 
where samples (discodermolide-treated cells vs. DMSO-treated control) were segregated on 
different sized gels (Figure 20, 21). 
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Figure 16: MALDI mass spectrum of spot A1 
 
Table 10: Database search result for spot A1.  Red bold text represents the matched peptide 
sequence within the complete sequence of stathmin. Sequence coverage: 18% 
 
Rank Protein 
Name 
Accession 
Number 
Protein 
MW 
Protein 
PI 
Peptide 
Count 
Protein 
Score 
Protein 
Score 
C.I. %
Total 
Ion 
Score 
Total 
Ion 
Score 
C.I. % 
Best Ion 
Score 
Best Ion 
Score C.I. 
% 
1 Stathmin 1 [Homo 
sapiens] 
gi|15680064 17325.9 5.76 2 135 100 120 100 77 100 
 
Peptide 
Number 
Calculated 
Mass 
Observed 
Mass 
Match 
Error 
Da 
Match 
Error 
PPM 
Start 
Position
End 
Position
Sequence Ion 
Score 
Ion Score 
C.I. % 
Modific
ation 
1 1388.7532 1388.7638 0.0106 8 15 27 ASGQAF
ELILSPR
77 100  
2 1541.8209 1541.826 0.0051 3 28 41 SKESVPE
FPLSPPK
42 99.9  
 
1 MASSDIQVKE LEKRASGQAF ELILSPRSKE SVPEFPLSPP KKKDLSLEEI  
51 QKKLEAAEER RKSHEAEVLK QLAEKREHEK EVLQKAIEEN NNFSKMAEEK  
101 LTHKMEANKE NREAQMAAKL ERLREKDKHI EEVRKNKESK DPADETEAD 
  
699.0 1361.8 2024.6 2687.4 3350.2 4013.0
Mass (m/z)
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Table 11: Comparison of theoretical fragment ions of the precursor m/z 1388.76 [M+H]+ ion 
with observed MS/MS ions. Red bold text represents the matched ions. 
 
 
Observed mass (S/N ratio > 10, increasing mass) 
754.5472   1188.8651   675.2676   827.4981   1030.5472   316.1245   564.3383   1214.8143   277.1194   341.1815 
803.3835   141.088       455.2275   390.4466    227.1389    404.1798   212.1358   219.1067     585.3499   425.2565 
787.3649   733.3005    1045.6155  175.1176    461.2084    342.1627   344.1561   562.2508     390.1839   785.4595 
917.4638   129.1074    415.1925    691.2664    112.0851    472.2663   255.1333   804.4049     359.1846   698.4545 
272.162 
 
 
Table 12: Comparison of theoretical fragmentation of the precursor m/z 1541.83 [M+H]+ ion 
with observed MS/MS values. Red bold text represents the matched ions. 
 
 
 
Observed mass (S/N ratio > 10, increasing)  
1478.0942    271.1662     129.1104     216.1142     584.334    1497.1174    1183.5425 
1115.6123    1298.7189   1490.1952   1389.7218   1491.801   211.1322     84.0837 
323.2235      1388.8489   531.298       1114.5524   1544.842   671.3597     904.4625 
1541.8344    785.472       341.2069     1201.6334   638.3813   1011.5574 
Seq ya yb 
  PEFPLS 643.35 671.34 
EFPLSP 643.35 671.34 
 PL 183.15 211.14 
# Immon. a a* a0 b b* b0 Seq y y* y0 #
1 60.04 60.04 42.03 88.04 70.03 S 1
2 101.11 188.14 171.11 170.13 216.13 199.11 198.12 K 1454.79 1437.76 1436.78 1
3 102.06 317.18 300.16 299.17 345.18 328.15 327.17 E 1326.69 1309.67 1308.68 1
4 60.04 404.21 387.19 386.20 432.21 415.18 414.20 S 1197.65 1180.63 1179.64 1
5 72.08 503.28 486.26 485.27 531.28 514.25 513.27 V 1110.62 1093.59 1092.61 1
6 70.07 600.34 583.31 582.33 628.33 611.30 610.32 P 1011.55 994.52 993.54 9
7 102.06 729.38 712.35 711.37 757.37 740.35 739.36 E 914.50 897.47 896.49 8
8 120.08 876.45 859.42 858.44 904.44 887.42 886.43 F 785.46 768.43 767.45 7
9 70.07 973.50 956.47 955.49 1001.49 984.47 983.48 P 638.39 621.36 620.38 6
1 86.10 1086.58 1069.56 1068.57 1114.58 1097.55 1096.57 L 541.33 524.31 523.32 5
1 60.04 1173.62 1156.59 1155.60 1201.61 1184.58 1183.60 S 428.25 411.22 410.24 4
1 70.07 1270.67 1253.64 1252.66 1298.66 1281.64 1280.65 P 341.22 324.19 3
1 70.07 1367.72 1350.69 1349.71 1395.72 1378.69 1377.71 P 244.17 227.14 2
1 101.11 K 147.11 130.09 1
# Immon. a a* a0 b b* b0 Seq y y* y0 #
1 44.05 44.05 72.04 A 1
2 60.04 131.08 113.07 159.08 141.07 S 1317.72 1300.69 1299.71 1
3 30.03 188.10 170.09 216.10 198.09 G 1230.68 1213.66 1212.67 1
4 101.07 316.16 299.14 298.15 344.16 327.13 326.15 Q 1173.66 1156.64 1155.65 1
5 44.05 387.20 370.17 369.19 415.19 398.17 397.18 A 1045.60 1028.58 1027.59 9
6 120.08 534.27 517.24 516.26 562.26 545.24 544.25 F 974.57 957.54 956.56 8
7 102.06 663.31 646.28 645.30 691.31 674.28 673.29 E 827.50 810.47 809.49 7
8 86.10 776.39 759.37 758.38 804.39 787.36 786.38 L 698.46 681.43 680.45 6
9 86.10 889.48 872.45 871.47 917.47 900.45 899.46 I 585.37 568.35 567.36 5
1 86.10 1002.56 985.54 984.55 1030.56 1013.53 1012.55 L 472.29 455.26 454.28 4
1 60.04 1089.59 1072.57 1071.58 1117.59 1100.56 1099.58 S 359.20 342.18 341.19 3
1 70.07 1186.65 1169.62 1168.64 1214.64 1197.62 1196.63 P 272.17 255.15 2
1 129.11 R 175.12 158.09 1
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Figure 17: MALDI mass spectrum of spot A2 
 
Table 13: Comparison of theoretical fragmentation of the precursor m/z 1241.63 [M+H[+ ion 
with observed MS/MS values. Red bold text represents the matched ions. 
 
 
                                                                                                                                                                                    
  
 
Observed mass (S/N ratio > 10, increasing)  
288.2281    435.2228    504.2939    1185.3153    88.0927      125.2726    681.4937 
433.2856    1189.847    581.3318    336.1622      1197.9047  129.0966    450.303 
303.2187    579.363      1241.7217  175.1171 
 
Seq ya yb 
TFVL 433.28 461.28 
# Immon. a a* a0 b b* b0 Seq y y* y0 #
1 60.04 60.04 42.03 88.04 70.03 S 1
2 74.06 161.09 143.08 189.09 171.08 T 1154.62 1137.59 1136.61 9
3 120.08 308.16 290.15 336.16 318.15 F 1053.57 1036.55 1035.56 8
4 72.08 407.23 389.22 435.22 417.21 V 906.50 889.48 888.49 7
5 86.10 520.31 502.30 548.31 530.30 L 807.44 790.41 789.43 6
6 88.04 635.34 617.33 663.34 645.32 D 694.35 677.33 676.34 5
7 102.06 764.38 746.37 792.38 774.37 E 579.33 562.30 561.31 4
8 120.08 911.45 893.44 939.45 921.44 F 450.28 433.26 3
9 101.11 1039.55 1022.52 1021.54 1067.54 1050.51 1049.53 K 303.21 286.19 2
1 129.11 R 175.12 158.09 1
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Table 14: Database search result of spot A2.  Red bold text represents the matched peptide 
sequence within the complete sequence of EEF1G. Sequence coverage: 18% 
 
Rank Protein 
Name 
Accession 
Number 
Protein 
MW 
Protein 
PI 
Peptide 
Count
Protein 
Score
Protein 
Score 
C.I. %
Total 
Ion 
Score
Total Ion 
Score C.I. 
% 
Best Ion 
Score 
Best Ion 
Score C.I. 
% 
1 
EEF1G 
protein 
[Homo 
sapiens] 
gi|39644794 49814 6.27 8 62 99.681 27 97.294 27 97.294 
 
Peptide 
Number 
Calculated 
Mass 
Observed 
Mass 
Match 
Error 
Da 
Match 
Error 
PPM 
Start 
Position
End 
Position
Sequence Ion 
Score 
Ion 
Score 
C.I. % 
Modific
ation 
1 821.45 821.46 0.0154 19 147 153 TFLVGER       
2 1118.68 1118.67 -0.005 -4 135 144 ILGLLDAYL
K 
      
3 1241.65 1241.63 -0.0192 -15 283 292 STFVLDEFK
R 
27 97.294   
4 1274.78 1274.76 -0.0173 -14 134 144 RILGLLDAY
LK 
      
5 1347.73 1347.70 -0.0325 -24 15 27 ALIAAQYS
GAQVR 
      
6 1399.66 1399.69 0.0321 23 1 11 GTLYTYPE
NWR 
      
7 1684.77 1684.76 -0.0153 -9 412 425 EYFSWEGA
FQHVGK 
      
18 1707.87 1707.85 -0.0184 -11 28 42 VLSAPPHFH
FGQTNR 
      
 
1 GTLYTYPENW RAFKALIAAQ YSGAQVRVLS APPHFHFGQT NRTPEFLRKF  
51 PAGKVPAFEG DDGFCVFESN AIAYYVSNEE LRGSTPEAAA QVVQWVSFAD  
101 SDIVPPASTW VFPTLGIMHH NKQATENAKE EVRRILGLLD AYLKTRTFLV  
151 GERVTLADIT VVCTLLWLYK QVLEPSFRQA FPNTNRWFLT CINQPQFRAV  
201 LGEVKLCEKM AQFDAKKFAE TQPKKDTPRK EKGSREEKQK PQAERKEEKK  
251 AAAPAPEEEM DECEQALAAE PKAKDPFAHL PKSTFVLDEF KRKYSNEDTL  
301 SVALPYFWEH FDKDGWSLWY SEYRFPEELT QTFMSCNLIT GMFQRLDKLR  
351 KNAFASVILF GTNNSSSISG VWVFRGQELA FPLSPDWQVD YESYTWRKLD  
401 PGSEETQTLV REYFSWEGAF QHVGKAFNQG KIFK  
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Figure 18: Regulation of stathmin activity during the cell cycle [excerpted from Mistry and 
Atweh, ref. 54] 
 
 
Figure 19: The working phase of the protein elongation process [excerpted from Thornton et al., 
ref. 55] 
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Figure 20: Protein distribution map of discodermolide-treated H460 human non-small cell lung 
cancer cells after electrophoresis in 11 cm gel 
 
Table 15: Protein profile based on the gel image shown in Figure 20 
 
Index Protein Name Accession # Protein 
Mw 
Protein 
pI 
Peptide 
Count 
1 Tumor rejection antigen-1 (gp96); glucose regulated 
protein, 94 k 
gi|4507677 92411 4.76 26 
2 Chaperone; heat shock 90kDa protein 1, beta gi|20149594 83212 4.97 21 
3 valosin-containing protein; yeast Cdc48p homolog; 
transitional endoplasmic reticulum ATPase  
gi|6005942 89265 5.14 25 
4 heat shock 70kDa protein 5 (glucose-regulated 
protein, 78kDa); BiP 
gi|16507237 72288 5.07 21 
5 thyroid hormone binding protein precursor gi|339647 57068 4.82 6 
6 Not identified     
7 prolyl 4-hydroxylase, beta subunit gi|20070125 57080 4.76 23 
8 N/I     
9 Chain A, Ribonuclease Inhibitor-Angiogenin 
Complex 
gi|3892017 49810 4.71 6 
10 vimentin [Homo sapiens] gi|5030431 41537 4.82 17 
11 Beta 5-tubulin [Homo sapiens] gi|18088719 49639 4.75 19 
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12 tubulin alpha 6 [Homo sapiens] gi|14389309 49863 4.96 18 
13 protein disulfide isomerase-related protein 5 gi|1710248 46170 4.95 10 
14 chaperonin containing TCP1, subunit 5 (epsilon) 
[Homo sapiens] 
gi|24307939 59632 5.45 12 
15 chaperonin containing TCP1, subunit 8 (theta)  gi|42662316 59582 5.42 10 
16 keratin 8; cytokeratin 8; keratin, type II cytoskeletal 8 
[Homo sapiens] 
gi|4504919 53671 5.52 26 
17 cytovillin 2 gi|340217 68119 5.8 7 
18 ALDH3A1 protein [Homo sapiens] gi|33871063 57473 6.96 10 
19 chaperonin containing TCP1, subunit 2 (beta) gi|5453603 57452 6.01 11 
20 human rab GDI [Homo sapiens] gi|285975 50631 5.94 13 
21 eukaryotic translation elongation factor 1 gamma; 
elongation factor 1-gamma 
gi|4503481 50087 6.25 9 
22 proliferation-associated 2G4, 38kDa  gi|5453842 43785 6.13 14 
23 Mitochondrial Aconitase 2 [Homo sapiens] gi|20072188 85511 7.62 9 
24 Far upstream element binding protein 1 (FUSE 
binding protein 1) (FBP) (DNA helicase V) (HDH V) 
gi|37078490 67431 7.18 17 
25 N/I     
26 uridine diphosphoglucose dehydrogenase  gi|7431380 55058 7.06 12 
27 isocitrate dehydrogenase 1 (NADP+), soluble; 
oxalosuccinate decarboxylase 
gi|28178825 46629 6.53 13 
28 F-actin capping protein alpha-1 subunit; Cap Z  gi|5453597 32902 5.45 5 
29 cytosolic inorganic pyrophosphatase gi|11056044 32639 5.54 11 
30 Chain A, Human Heart L-Lactate Dehydrogenase H 
Chain, Ternary Complex With Nadh And Oxamate 
gi|13786847 36484 5.72 11 
31 protein phosphatase 1, catalytic subunit, beta isoform 
1; protein phosphatase 1, catalytic subunit, 
gi|4506005 37162 5.84 5 
32 transaldolase 1; dihydroxyacetone transferase; 
glycerone transferase [Homo sapiens] 
gi|5803187 37516 6.36 11 
33 annexin I; annexin I (lipocortin I); lipocortin I gi|4502101 38689 6.57 13 
34 poly(rC) binding protein 1; poly(rC)-binding protein 1 
[Mus musculus] 
gi|6754994 37473 6.66 5 
35 heterogeneous nuclear ribonucleoprotein homolog 
JKTBP [imported] - human 
gi|7446333 33568 6.85 6 
36 esterase D/formylglutathione hydrolase; Esterase D; 
S-formylglutathione hydrolase  
gi|33413400 31442 6.54 9 
37 cytosolic malate dehydrogenase; soluble malate 
dehydrogenase [Homo sapiens] 
gi|5174539 36403 6.91 5 
38 aldo-keto reductase family 1, member B10; aldose 
reductase-like 1; aldo-keto reductase family 1 
gi|20127592 35997 7.12 6 
39 glyceraldehyde-3-phosphate dehydrogenase gi|31645 36031 8.26 7 
40 aldo-keto reductase [Homo sapiens] gi|3493209 35996 7.67 7 
41 nascent-polypeptide-associated complex alpha 
polypeptide [Homo sapiens] 
gi|5031931 23369 4.52 5 
42 14-3-3 gamma protein [Homo sapiens] gi|5726310 28356 4.66 4 
43 N/I     
44 chromobox homolog 3; heterochromatin protein HP1 
gamma;  
gi|15082258 20798 5.23 5 
45 eukaryotic translation initiation factor 5A; eIF5AI 
[Homo sapiens] 
gi|4503545 16821 5.08 2 
46 dUTP pyrophosphatase [Homo sapiens] gi|4503423 17736 6.15 8 
47 thioredoxin peroxidase; thioredoxin peroxidase 
(antioxidant enzyme) [Homo sapiens] 
gi|5453549 30520 5.86 9 
48 glutathione-S-transferase omega 1; glutathione-S- gi|4758484 27548 6.23 5 
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transferase like; glutathione transferase omega  
49 peroxiredoxin 3 isoform b; antioxidant protein 1; 
thioredoxin-dependent peroxide reductase precursor 
gi|32483377 25822 7.04 4 
50 DJ-1 protein, DNA-binding protein regulatory subunit 
- human 
gi|7429593 19834 6.33 10 
51 Chain A, Horf6 A Novel Human Peroxidase Enzyme gi|3318841 25011 6 12 
52 proteasome alpha 1 subunit isoform 2;  gi|4506179 29536 6.15 12 
53 phosphoglycerate mutase 1 (brain); Phosphoglycerate 
mutase A, nonmuscle form  
gi|4505753 28785 6.67 6 
54 Chain A, Ligand-Free Human Glutathione S-
Transferase M1a-1a 
gi|4388890 25564 6.28 6 
55 Chain A, The Structure Of Holo Type Human Cu, Zn 
Superoxide Dismutase 
gi|31615344 15794 5.7 3 
56 N/I     
57  Crystal Structure Of A Human Low Molecular 
Weight Phosphotyrosyl Phosphatase.   
gi|3891774 17899 6.35 6 
58-62 N/I     
63  Cdc42 From Human, Nmr, 20 Structures gi|2624582 21473 6.92 3 
64-66 N/I     
67 Synovial sarcoma, X breakpoint 5, isoform a  gi|16741685 26266 9.61 8 
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Figure 21: Protein distribution map of discodermolide-treated H460 human non-small cell lung 
cancer cells after electrophoresis in 17 cm gel 
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Table 16: Protein profile based on the gel image shown in Figure 21 
 
Index Protein Name Accession # Protein 
Mw 
Protein 
pI 
Peptide 
Count 
1 heterogeneous nuclear ribonucleoprotein H1  gi|5031753 49198 5.89 11 
2 Eukaryotic translation elongation factor 1 gamma 
[Homo sapiens] 
gi|15530265 50115 6.25 7 
3 GDP dissociation inhibitor 2; rab GDP-dissociation 
inhibitor, beta [Homo sapiens] 
gi|6598323 50630 6.11 14 
4 S-adenosylhomocysteine hydrolase gi|178277 47684 6.03 10 
5 annexin VII isoform 1; annexin VII (synexin); synexin 
[Homo sapiens] 
gi|4502111 50283 6.25 7 
6 protein phosphatase 1, catalytic subunit, beta isoform 
1; protein phosphatase 1, catalytic subunit, 
gi|4506005 37162 5.84 5 
7 tat-associated protein gi|1096067 30965 4.78 4 
8 tyrosine 3/tryptophan 5 -monooxygenase activation 
protein, epsilon polypeptide; 14-3-3 epsilon; mit 
gi|5803225 29155 4.63 12 
9 tyrosine 3-monooxgenase/tryptophan 5-monooxgenase 
activation protein, gamma polypeptide; 14-3-3 pro 
gi|9507245 28284. 4.8 12 
10 chloride intracellular channel 1; p64CLCP; chloride 
channel ABP  
gi|14251209 26905 5.09 2 
11 N/I     
12 TCTP; tumor protein, translationally-controlled 1; 
fortilin; histamine-releasing factor [Homo sapiens] 
gi|33285832 19581 4.98 7 
13 inorganic pyrophosphatase; cytosolic inorganic 
pyrophosphatase; inorganic pyrophosphatase 1; pyroph 
gi|11056044 32639 5.54 9 
14 proteasome activator subunit 3 isoform 2; Ki nuclear 
autoantigen; Ki antigen; proteasome activator  
gi|30410796 30867 5.79 12 
15 prohibitin [Homo sapiens] gi|4505773 29785 5.57 17 
16 ubiquitin carboxyl-terminal esterase L1 (ubiquitin 
thiolesterase); Ubiquitin C-terminal esterase L1 
gi|21361091 24808 5.33 13 
17 proteasome beta-subunit - human gi|631345 25892 5.7 5 
18 thioredoxin peroxidase; thioredoxin peroxidase 
(antioxidant enzyme) 
gi|5453549 30520 5.86 7 
19 N/I     
20 glutathione S-transferase-P1c [Homo sapiens] gi|726098 23355 5.43 8 
21 N/I     
22 proteasome beta 3 subunit; proteasome theta chain; 
proteasome chain 13; proteasome component C10-II 
gi|22538465 22933 6.14 10 
23 endoplasmic reticulum protein 29 precursor; 
endoplasmic reticulum lumenal protein ERp28 [Homo 
sapiens] 
gi|5803013 28975 6.77 9 
24 proteasome beta 2 subunit; proteasome subunit, beta 
type, 2; macropain subunit C7-I; multicatalytic 
gi|4506195 22821 6.51 6 
25 Chain A, Crystal Structure Of The K130r Mutant Of 
Human Dj-1 
gi|33358055 20970 6.5 7 
26 Proteasome alpha 1 subunit, isoform 2 [Homo sapiens] gi|13543551 29578 6.15 8 
27 von Hippel-Lindau binding protein 1; VHL binding 
protein-1; prefoldin 3 [Homo sapiens] 
gi|4507873 22611 6.63 7 
28 esterase D/formylglutathione hydrolase; Esterase D; S-
formylglutathione hydrolase  
gi|33413400 31442 6.54 9 
29 voltage-dependent anion channel 2 [Homo sapiens] gi|42476281 31546 7.49 9 
30 heterogeneous nuclear ribonucleoprotein A2/B1 gi|4504447 35983 8.67 12 
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isoform A2; heterogeneous nuclear ribonucleoprotein 
B 
31 Annexin A2 [Homo sapiens] gi|16306978 38593 7.57 18 
32 Chain A, Crystal Structure Of Human Dt-Diaphorase 
(Nad(P)h Oxidoreductase) 
gi|7766987 30659 8.91 7 
33 proteasome alpha 4 subunit;PSMA4 gi|4506185 29465 7.57 7 
34 Calcyclin binding protein  gi|45709259 26165 7.63 3 
35 electron-transfer-flavoprotein, beta polypeptide gi|4503609 27826 8.24 10 
36 eukaryotic translation initiation factor 4H isoform 2  gi|14702180 25184 7.79 6 
37 proteasome alpha 2 subunit ;PSMA2 protein  gi|39644890 24853 7.08 9 
38 proteasome beta 2 subunit; proteasome subunit, beta 
type, 2; macropain subunit C7-I;  
gi|4506195 22821 6.51 7 
39 ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit, isoform 1, cardiac muscle;  
gi|4757810 59713 9.16 14 
40 RAN protein [Homo sapiens] gi|32425497 25206 7.16 5 
41 biliverdin-IX beta reductase isozyme I {EC 1.3.1.24} 
[human, liver, Peptide, 204 aa] 
gi|544759 21846 7.31 7 
42 prostatic binding protein; phosphatidylethanolamine 
binding protein  
gi|4505621 21043 7.01 5 
43 eukaryotic translation initiation factor 5A; eIF5AI 
[Homo sapiens] 
gi|4503545 16821 5.08 8 
44 translation initiation factor eIF-4C - human gi|1082871 16460 5.07 4 
45 N/I     
46 dUTP pyrophosphatase  gi|4503423 17736 6.15 8 
47 Chain A, X-Ray Structure Of Human Nucleoside 
Diphosphate Kinase A Complexed With Adp At 2 A 
Resolut 
gi|37928159 17096 5.67 7 
48 nucleoside-diphosphate kinase 1 isoform b [Homo 
sapiens] 
gi|4557797 17137 5.83 7 
49 Stathmin 1 [Homo sapiens] gi|15680064 17325 5.76 2 
50 N/I     
51 histone H3 gi|386772 15238 10.99 6 
52 H2B histone family, member J  gi|4504269 13883 10.31 7 
53 N/I     
54 Chain A, Structure Of Arf1-Gdp Bound To Sec7 
Domain Complexed With Brefeldin A 
gi|40889633 18788 5.63 4 
55 prefoldin 2 [Homo sapiens] gi|12408675 16637 6.2 5 
56 N/I     
57 basic transcription factor 3; nascent-polypeptide-
associated complex beta polypeptide [Homo sapiens 
gi|20070130 17688 6.85 3 
58 peptidylprolyl isomerase A; cyclophilin A [Mus 
musculus] 
gi|6679439 17959 7.74 5 
59 N/I     
60 40S ribosomal protein S12 gi|133742 14516 6.3 3 
61 Chain A, Cyclophilin A Complexed With Cyclosporin 
A (Nmr, 22 Structures) 
gi|1431788 17980 7.44 5 
62 Peptidylprolyl isomerase A (cyclophilin A) [Homo 
sapiens] 
gi|13937981 17999 7.68 11 
63 destrin (actin depolymerizing factor) [Homo sapiens] gi|5802966 18493 8.06 3 
64 cofilin 1 (non-muscle) [Homo sapiens] gi|5031635 18490 8.22 8 
65 anterior gradient 2 homolog; secreted cement gland 
homolog; anterior gradient 2 homolog (Xenepus la 
gi|5453541 19966 9.03 8 
66 nucleoside-diphosphate kinase 2; non-metastatic cells 
2, protein (NM23) expressed in; c-myc transcr 
gi|4505409 17286 8.52 3 
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67 Chain A, Cyclophilin A gi|1633054 17869 7.82 6 
68 Chain A, Human Mitochondrial Single-Stranded Dna 
Binding Protein 
gi|2624694 15185 8.23 10 
69-70 N/I     
71 Putative S100 calcium-binding protein 
H_NH0456N16.1 
gi|13431875 11501 8.83 2 
72 Chain A, Macrophage Migration Inhibitory Factor 
(Mif) With Hydroxphenylpyruvate 
gi|5542151 12337 8.24 2 
73 S100 calcium-binding protein A10; S100 calcium-
binding protein A10 (annexin II ligand, calpactin I, 
gi|4506761 11195 6.82 3 
74 dJ908M14.1.3 (ribosomal protein S21, isoform 3) 
[Homo sapiens] 
gi|12964241 9887 7.71 2 
75 S100 calcium-binding protein A4; S100 calcium-
binding protein A4 (calcium protein, calvasculin, met 
gi|4506765 11720 5.85 4 
76 N/I     
77  Thioredoxin (Reduced Form) gi|230939 11699 4.82 3 
78 Chain D, Crystal Structure Of Edema Factor 
Complexed With Calmodulin 
gi|18655708 16268 4.11 4 
79 Eukaryotic translation initiation factor 4E  gi|15214959 25080 6 1 
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3. FUTURE PLANS 
 
3.1. PROTEIN SAMPLE FRACTIONATION 
 
In the current experiments, 17 cm pH 3-10, non-linear IPG strips were used in isoelectric 
focusing and 183 × 193 × 1 mm Tris-HCl gel for second dimension separation. One of two spots 
that were found to have an expression level change is stathmin. As seen in the mass spectrum 
shown in Figure 15, a pair of ions at m/z 1388.7/1294.3 represents a phosphopeptide (15-27) with 
the sequence ASGQAFELILSPR.  It is not known yet which serine is phosphorylated within this 
sequence. Interestingly, no other phosphorylated stathmin isoforms were detected. Muller, et al. 
reported a mass spectrometric method, which characterized stathmin isoforms separated on 2D 
PAGE. In their experiments, a pH 4-7 linear IPG strip were soaked in sample solution and a 20 × 
25 cm SDS-PAGE gel was used to run second dimensional electrophoresis overnight. Multiple 
isoforms of phosphorylated stathmin were identified from the Coomassie Brilliant Blue G250 
stained gel (Figure 22) [63]. This result provides a good example and is encouraging. In future 
experiments, a narrow range IPG strip will be used to exclude excessive information while 
expanding the region of interested.  
 
3.2. SATURATION LABELING 
 
To avoid the gel-to-gel variation in traditional 2D PAGE, 2D DiGE was employed in the present 
experiments. Two mass and charge-matched cyanine dyes (Cy3 and Cy5) were used in a 
minimal labeling manner. Even as the dyes undoubtedly offer benefits to image analysis, there 
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are a few limitations due to the nature of the labeling reaction. Firstly, the dye to protein ratio is 
kept deliberately low (less than 5%) in order to avoid multiple dye additions on each protein 
molecule, which would lead to more than one spot per protein on a 2D gel. Due to the high 
lysine content of most proteins (e.g., 10.1% across eight random proteins [64]) it would be 
difficult to force the labeling reaction to saturation without the need for excessive amounts of 
dyes. Therefore, the sensitivity of the minimal labeling dyes could be further enhanced. 
Secondly, the fact that less than 5% of protein is labeled means that the unlabeled bulk runs with 
a higher mobility because the dye itself has a mass of 434-464 Da. This will make precise spot 
excision a problem in practice. Post-staining is necessary to match spots on the images. To 
improve the sensitivity and to overcome the problem in spot picking, a new labeling strategy is 
proposed to use which allows the saturated labeling on an alternative, less prevalent amino acid 
residue. Cysteine is one of such residues which are about 2.47% across eight random proteins 
[64]. The reactive thiol group of cysteine reacts with maleimide through nucleophilic addition to 
form a thioester (Figure 23) [65]. We could try in the future two kinds of new maleimide cyanine 
dyes commercially available from Amersham Biosciences. 
 
Figure 22: 2D PAGE separation of stathmin isoforms with major phosphorylated components 
indicated. In this case IEF was performed on linear pH 4-7 IPG strips [excerpted from Müller et 
al., ref. 63]. 
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Figure 23: Schematic of labeling reaction of protein thiols with maleimide cyanine dyes 
[excerpted from Shaw et al., ref. 65]. 
 
3.3. APPLICATION OF HPLC TO PROTEIN MIXTURE SEPARATION AND 
PROTEIN IDENTIFICATION 
 
Even though samples were carefully handled in all steps of labeling, separation and tryptic 
digestion, there were still a large number of spots that could not be identified successfully. These 
spots might be of small amounts (5-25 µg) or have a mixture of multiple peptides, which leads to 
unsolved problem in database search. The researchers at Applied Biosystems have recently 
developed a simple step elution-based 2-D peptide chromatography setup. This facility consists 
of an UltiMate nano HPLC system (Dionex), a FAMOS autosampler (Dionex) and a Probot 
microfraction collector (Dionex) and features an increased sample loading capacity and resolving 
power. By using this LC-MALDI approach, intermediate amounts (5-25 µg) of complex 
proteomic samples can be separated into multiple fractions and each fraction can further be 
washed off as continuous tiny droplets, which are then spotted on MALDI plates.  Database 
searching with different available software, e.g., Sequest from ThermoFinnigan, may be useful in 
the identification of protein samples when data from all fractions is combined. 
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3.4. POTENTIAL TARTETS THAT MIGHT HAVE PROTEOMIC CHANGES 
 
Two strategies are currently employed in the exploration of proteomic changes. The passive 
strategy is to run 2-D electrophoresis followed by image analysis. While on the other hand, the 
active strategy is to adjust and optimize the experimental design to the predicted targets to see if 
there really exist some changes. As the depth of this project increases, an intentional move 
toward the active strategy can be made based on the accumulated data and knowledge. As 
microtubule stabilization proceeds toward arrest at the G2/M phase and further the induction of 
apoptosis, it could be assumed that proteins associated with cell cycle and microtubule dynamics 
should have some proteomic changes, either in expression or in post-translational modification. 
As mentioned previously, microtubule-servering associated with unregulated EEF1A may be a 
contributor to the cell death [59]. Thus, EEF1A could be one of the next targets to which 
attention should be paid. Another target would be microtubule associated proteins (MAPs) 
because they are in intimate relation with microtubule dynamics. In addition, the accumulating 
evidence has suggested that molecular changes including overexperssion of oncogenes and 
decreased expression of tumor suppressor genes are responsible for lung carcinogenesis [66]. 
Liu, Y. et al. has compared the protein expression changes of human non-small cell lung cancer 
(NSCLC) cell lines with normal human bronchial epithelial cell lines [67]. Eight proteins 
including EEF1Bβ, vimentin, cytokeratin 8, YB-1, PCNA, Nm23, hnPNP A2/B1, and HSP90β 
were found to up-regulated in lung cancer cells, and the tumor suppressor protein 14-3-3σ was 
found to be down-regulated. Chang, et al. also reported a comparison study, in which antioxidant 
enzyme peroxiredoxin I was identified to be overexpressed because of the continuous exposure 
of human lung to oxidative stress. Obviously, these proteins should be taken into consideration in 
subsequent studies. 
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